The past 10 years have seen the publication of results from several multicentre clinical trials
in primary and systemic sclerosis (SSc)-related Raynaud phenomenon. The publication of …

This society aims to further develop the specialty of vascular medicine in Europe in order to
improve the vascular health of the population and the overall quality of life and health status …

There are two major clinical subsets of scleroderma:(i) systemic sclerosis (SSc) is a complex
systemic autoimmune disorder characterized by inflammation, vasculopathy, and excessive …

Objective To assess the efficacy of therapies in healing and preventing digital ulcers (DUs)
in systemic sclerosis (SSc; scleroderma). Methods Medline and EMBASE databases, and …

Raynaud's phenomenon (RP) is a well defined clinical syndrome characterized by recurrent
episodes of digital vasospasm triggered by exposure to physical/chemical or emotional …

Systemic sclerosis (SSc) is an acquired multiorgan connective tissue disease with variable
mortality and morbidity dictated by clinical subset type. The etiology of the basic disease and …

Raynaud's phenomenon (RP) is a major cause of pain and disability in patients with
autoimmune connective tissue diseases (CTDs), particularly systemic sclerosis (SSc). The …

Raynaud's phenomenon is caused by episodic vasospasm and ischaemia of the extremities
in response to cold or emotional stimuli, which result in a characteristic triphasic colour …

Systemic sclerosis is an uncommon autoimmune connective tissue disease with multiorgan
system involvement and significant associated morbidity and mortality. Cutaneous signs and …

Raynaud's phenomenon is a common condition characterized by vasospasm of the digital
arteries and resulting cyanosis and redness. It often does not require pharmacologic …